| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2026―Aug―24 |
Ensitrelvir (Xocova) for Post-Exposure Prophylaxis of COVID-19 |
|
| 2 |
[GO] |
2025―Oct―09 |
COVID-19 Update: 2025-2026 Vaccine Formulations and Recommendations |
|
| 3 |
[GO] |
2025―Aug―26 |
COVID-19 Update: Full Approval for Novavax COVID-19 Vaccine |
|
| 4 |
[GO] |
2025―Aug―26 |
COVID-19 Update: mRNA COVID-19 Vaccines and Myocarditis |
|
| 5 |
[GO] |
2025―Aug―26 |
COVID-19 Update: mNEXSPIKE - A New Moderna mRNA Vaccine for COVID-19 |
|
| 6 |
[GO] |
2024―Oct―10 |
COVID-19 Update: Novavax Vaccine for 2024-2025 |
|
| 7 |
[GO] |
2024―Oct―01 |
Addendum: Effectiveness of mRNA COVID-19 Vaccines |
|
| 8 |
[GO] |
2024―Sep―19 |
COVID-19 Update: New Pfizer and Moderna Vaccine Formulations for 2024-2025 |
|
| 9 |
[GO] |
2024―May―15 |
COVID-19 Update: An EUA for Pemivibart (Pemgarda) for Pre-Exposure Prophylaxis |
|
| 10 |
[GO] |
2023―Dec―11 |
Vaccination Recommendations for Updated 2023-2024 COVID-19 Vaccines |
|
| 11 |
[GO] |
2023―Nov―21 |
COVID-19 Update: New Novavax Vaccine Formulation for 2023-2024 |
|
| 12 |
[GO] |
2023―Oct―03 |
COVID-19 Update: New Pfizer and Moderna Vaccine Formulations for 2023-2024 |
|
| 13 |
[GO] |
2023―Jul―26 |
Dosing Recommendations for Novavax and Johnson and Johnson COVID-19 Vaccines |
|
| 14 |
[GO] |
2023―Jul―26 |
Vaccination Recommendations for Bivalent mRNA COVID-19 Vaccines |
|
| 15 |
[GO] |
2023―May―11 |
COVID-19 Update: Metformin to Prevent Long Covid? |
|
| 16 |
[GO] |
2023―May―11 |
COVID-19 Update: An EUA for Vilobelimab (Gohibic) for COVID-19 |
|
| 17 |
[GO] |
2023―Mar―30 |
COVID-19 Update: Pfizer Bivalent Vaccine Booster Dose for Children 6 Months to 4 Years Old |
|
| 18 |
[GO] |
2023―Mar―16 |
Antiviral Drugs for COVID-19 in Vaccinated Outpatients |
|
| 19 |
[GO] |
2023―Feb―14 |
COVID-19 Update: Evusheld Unlikely to Neutralize XBB.1.5 Omicron Variant |
|
| 20 |
[GO] |
2023―Jan―17 |
COVID-19 Update: Tocilizumab (Actemra) FDA-Approved for Treatment of COVID-19 (online only) |
|
